RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if RAD001, to a maximum dose of 10 mg/day, can be
safely administered with cisplatin, and concurrent radiotherapy, for patients with locally
advanced, inoperable, squamous cell carcinoma of the head and neck.
Phase:
Phase 1
Details
Lead Sponsor:
howard safran
Collaborators:
Memorial Hospital of Rhode Island Rhode Island Hospital Roger Williams Medical Center The Miriam Hospital